Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227994 · ClinicalTrials.gov registry record · Phase 4
Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00227994 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 40 participants.
The verdict
NCT00227994, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors.
Interventions
- DRUG Donepezil
- DRUG Galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227994
The ClinicalTrials.gov registry entry for NCT00227994 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Donepezil is the first listed.
NCT00227994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00227994 about?
NCT00227994 is a clinical study titled "Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke". This study will evaluate the effectiveness of treatment with acetylcholinesterase inhibitors in improving cognitive function and overall rehabilitation in elderly stroke survivors.
What is the current status of trial NCT00227994?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2003-04. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00227994?
The interventions under investigation include: Donepezil (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT00227994?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.